Nasal Steroids in Controlled Glaucoma

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Oct 17, 2008

Keywords

ClinConnect Summary

Systemic and topical ophthalmic steroids have long been associated with ocular effects, such as glaucoma or cataracts. Periocular steroid injections and steroids applied to periocular skin have also been reported to increase intraocular pressure (IOP) and raised IOP is the major risk factor for glaucoma. Approximately 18 to 36% of the general population are corticosteroid responders. This response is increased to 46 to 92% in patients with primary open-angle glaucoma (POAG).

Allergic rhinitis affects up to 30% of adults and 40% of children in the United States. Topical nasal steroids are t...

Gender

ALL

Eligibility criteria

• Inclusion criteria included the following:
• • age 18 to 85 years inclusive
• • OHT or mild to moderate POAG with cup-disc ratio of less than 0.8 vertically and mean deviation of less than -12.00 dB on Humphrey perimetry
• • well controlled disease defined by IOP being at target and no visual field or disc progression for a minimum of 6 months
• Exclusion criteria included the following:
• • any form of steroid medication use within the last 6 weeks
• • previous intra-ocular or refractive surgery
• • no light perception vision.
• • Patients with or without rhinitis (allergic/ non-allergic/ mixed), with rhinitis defined as allergies and/ or nasal congestion present for greater than one year, were eligible.